![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, January 23, 2018 10:04:21 PM
1st trial: Opdivo vs Dacarbazine (chemo):
Opdivo: Complete Response Rate (CRR): 4%, Objective Response Rate (ORR): 34%
Dacarbazine: CRR: 1%, ORR: 9%
2nd trial: Opdivo+Yervoy vs Opdivo vs Yervoy
Opdivo+Yervoy: CRR: 8.9%, ORR: 50%
Opdivo: CRR: 8.5%, ORR: 40%
Yervoy: CRR: 1.9%, ORR: 14%
Opdivo Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf (pp. 41-44)
------------------
EP IL-12 + Keytruda complete response rate is stunning at >40%
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM